Associate Professor Shyamal Das
Position | Associate Professor and Associate Dean (Research) |
---|---|
Qualifications | MPharm PhD |
Research summary | Drug formulation and delivery, drug delivery to the lung |
Teaching | Teaching:
Co-ordination:
|
Memberships |
|
Research
- Google Scholar citation profiles
- Scopus Author ID: 55476992200
The research interests of Associate Professor Das revolve around drug delivery, in particular, respiratory drug delivery of powder formulations for treating chronic lung conditions such as COPD, asthma, tuberculosis, lung cancer and lung infections.
His aim is to achieve a fundamental knowledge base on solid state characterisation processes to understand various pharmaceutical processes such as milling, mixing, spray drying, amorphisation, micronisation, crystallisation, relaxation, dissolution, coating and storage. These knowledge and innovating approaches can be used to develop various conventional and controlled release solid dosage forms such as powders for respiratory delivery as well as tablets and capsules for oral delivery.
Associate Professor Das has extensive research networks with collaborators in New Zealand, Australia, Europe, Asia, the United Kingdom and the USA.
For more visit Das laboratory
PhD projects available
Please contact me if you are interested in conducting PhD research in the following areas:
- Interactions and influence of lung surfactant on dissolution in the lung
- Solid surface characteristics that influence powder delivery to the lung
Biography
Associate Professor Shyamal Das lectures in Pharmaceutical Science at the School of Pharmacy, University of Otago. He is an internationally recognised formulation expert with over 15 years of experience in dry powder inhaler technology.
Associate Professor Das supervises a large productive research group which focuses on drug delivery to the lung to improve therapy for chronic lung conditions such as asthma, chronic obstructive pulmonary disease, cystic fibrosis and tuberculosis. He is currently contributing to the development of inhalers to treat coronaviruses in collaboration with academia and industries.
Associate Professor Das completed his PhD and research fellowships at Monash Institute of Pharmaceutical Sciences. He was a visiting researcher at the University College London (UK), Imperial College London (UK) and the University of Texas at Austin (USA).
Associate Professor Das is also an award-winning passionate lecturer. He has won multiple awards for best teaching and supervision at the University of Otago.
Additional details
Previous positions
- Research Fellow, Monash Institute of Pharmaceutical Sciences, Monash University, Australia (2008–2013)
- Teaching Assistant, Department of Pharmaceutics and Department of Pharmacy Practice, Monash University, Australia (2005–2008)
- Assistant Professor, Department of Pharmacy, Jahangirnagar University, Bangladesh (2003–2004)
- Lecturer, Department of Pharmacy, Jahangirnagar University, Bangladesh (2000–2003)
Teaching and research awards
- Winner of the Otago University Students’ Association’s 2017 Teaching Excellence Award: Premier Lecturer Award 2017 Division of Health Sciences
- Winner of the Otago University Students’ Association’s Supervisor of the Year Award 2017 Division of Health Sciences
- Winner of the School of Pharmacy’s Excellence in Teaching Award 2016
- Winner of the Otago University Students’ Association’s 2016 Teaching Excellence Award (Top Five Teacher)
- Winner of the Otago School of Pharmacy’s Emerging Researcher Award 2016
- Finalist (top five) for the Australasian Pharmaceutical Scientists Association’s 2016 Early Career Investigator Award
- Health Research Council of New Zealand’s Emerging Researcher First Grant 2015
School of Pharmacy administrative roles
- Chair, BPharm(Hons) Committee (since 2014)
- Co-Chair, School of Pharmacy Research Committee (since 2020) and Member since February 2017)
- Member, Research and Postgraduate Committee (since March 2019)
- Member, School of Pharmacy Undergraduate Programmes Committee
- Member, School of Pharmacy BPharm/BPharm(Hons) Curriculum Committee (since November 2017)
- Self-Review Coordinator of BPharm(Hons) Programme (2018)
- Member, School of Pharmacy Admission Working Party (June 2016 to June 2018)
Publications
Das, S., Rades, T., & McDowell, A. (2023). In honor of Professor Ian Tucker. International Journal of Pharmaceutics. Advance online publication. doi: 10.1016/j.ijpharm.2023.122762
Khadka, P., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2022). A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation. Drug Delivery & Translational Research. Advance online publication. doi: 10.1007/s13346-022-01238-y
Adhikari, B. R., & Das, S. C. (2022). Amorphicity and aerosolization of soluplus-based inhalable spray dried powders. Pharmaceutics, 14(12), 2618. doi: 10.3390/pharmaceutics14122618
Eedara, B. B., Bastola, R., & Das, S. C. (2022). Dissolution and absorption of inhaled drug particles in the lungs [Review]. Pharmaceutics, 14, 2667. doi: 10.3390/pharmaceutics14122667
Khadka, P., Tucker, I. G., & Das, S. C. (2022). In vitro dissolution testing of rifampicin powder formulations for prediction of plasma concentration-time profiles after inhaled delivery. Pharmaceutical Research. Advance online publication. doi: 10.1007/s11095-022-03439-z
Das, S. C., Khadka, P., Shah, R., McGill, S., & Smyth, H. D. C. (2021). Nanomedicine in pulmonary delivery. In P. Kesharwani, S. Taurin & K. Greish (Eds.), Theory and applications of nonparenteral nanomedicines. (pp. 319-354). London, UK: Elsevier. doi: 10.1016/B978-0-12-820466-5.00014-4
Chapter in Book - Research
Hadjittofis, E., Das, S. C., Zhang, G. G. Z., & Heng, J. Y. Y. (2017). Interfacial phenomena. In Y. Qiu, Y. Chen, G. G. Z. Zhang, L. Yu & R. V. Mantri (Eds.), Developing solid oral dosage forms: Pharmaceutical theory & practice. (2nd ed.) (pp. 225-252). London, UK: Academic Press. doi: 10.1016/B978-0-12-802447-8.00008-X
Chapter in Book - Research
Das, S. C., & Stewart, P. J. (2016). Understanding the respiratory delivery of high dose anti-tubercular drugs. In A. J. Hickey, A. Misra & P. B. Fourie (Eds.), Drug delivery systems for tuberculosis prevention and treatment. (pp. 258-274). Chichester, UK: Wiley. doi: 10.1002/9781118943182.ch13
Chapter in Book - Research
Adhikari, B. R., & Das, S. C. (2022). Amorphicity and aerosolization of soluplus-based inhalable spray dried powders. Pharmaceutics, 14(12), 2618. doi: 10.3390/pharmaceutics14122618
Journal - Research Article
Adhikari, B. R., Bērziņš, K., Fraser-Miller, S. J., Cavallaro, A., Gordon, K. C., & Das, S. C. (2022). Optimization of methionine in inhalable high-dose spray-dried amorphous composite particles using response surface method, infrared and low frequency Raman spectroscopy. International Journal of Pharmaceutics, 614, 121446. doi: 10.1016/j.ijpharm.2021.121446
Journal - Research Article
Adhikari, B. R., Dummer, J., Gordon, K. C., & Das, S. C. (2022). An expert opinion on respiratory delivery of high dose powders for lung infections. Expert Opinion on Drug Delivery. Advance online publication. doi: 10.1080/17425247.2022.2089111
Journal - Research Article
Adhikari, B. R., Gordon, K. C., & Das, S. C. (2022). Solid state of inhalable high dose powders. Advanced Drug Delivery Reviews. Advance online publication. doi: 10.1016/j.addr.2022.114468
Journal - Research Article
Adhikari, B. R., Sinha, S., Gordon, K. C., & Das, S. C. (2022). Amino acids improve aerosolization and chemical stability of potential inhalable amorphous spray-dried ceftazidime for Pseudomonas aeruginosa lung infection. International Journal of Pharmaceutics, 621, 121799. doi: 10.1016/j.ijpharm.2022.121799
Journal - Research Article
Adhikari, B. R., Sinha, S., Lyons, N., Pletzer, D., Lamont, I., Gordon, K. C., & Das, S. C. (2022). Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation. European Journal of Pharmaceutics & Biopharmaceutics. Advance online publication. doi: 10.1016/j.ejpb.2022.10.005
Journal - Research Article
Eedara, B. B., Bastola, R., & Das, S. C. (2022). Dissolution and absorption of inhaled drug particles in the lungs [Review]. Pharmaceutics, 14, 2667. doi: 10.3390/pharmaceutics14122667
Journal - Research Article
Khadka, P., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2022). A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation. Drug Delivery & Translational Research. Advance online publication. doi: 10.1007/s13346-022-01238-y
Journal - Research Article
Khadka, P., Tucker, I. G., & Das, S. C. (2022). In vitro dissolution testing of rifampicin powder formulations for prediction of plasma concentration-time profiles after inhaled delivery. Pharmaceutical Research. Advance online publication. doi: 10.1007/s11095-022-03439-z
Journal - Research Article
Saha, T., Quiñones‑Mateu, M. E., & Das, S. C. (2022). Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices. International Journal of Pharmaceutics. Advance online publication. doi: 10.1016/j.ijpharm.2022.122042
Journal - Research Article
Saha, T., Sinha, S., Harfoot, R., Quiñones Mateu, M. E., & Das, S. C. (2022). Manipulation of spray-drying conditions to develop an inhalable ivermectin dry powder. Pharmaceutics, 14(7), 1432. doi: 10.3390/pharmaceutics14071432
Journal - Research Article
Khadka, P., Sinha, S., Tucker, I. G., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2021). Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats. European Journal of Pharmaceutics & Biopharmaceutics, 162, 1-11. doi: 10.1016/j.ejpb.2021.02.011
Journal - Research Article
Khadka, P., Sinha, S., Tucker, I. G., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2021). Studies on the safety and the tissue distribution of inhaled high-dose amorphous and crystalline rifampicin in a rat model. International Journal of Pharmaceutics, 597, 120345. doi: 10.1016/j.ijpharm.2021.120345
Journal - Research Article
Momin, M. A. M., Adhikari, B. R., Sinha, S., Larson, I., & Das, S. C. (2021). Roflumilast powders for chronic obstructive pulmonary disease: Formulation design and the influence of device, inhalation flow rate, and storage relative humidity on aerosolization. Pharmaceutics, 13, 1254. doi: 10.3390/pharmaceutics13081254
Journal - Research Article
Adhikari, B. R., Bērziņš, K., Fraser-Miller, S. J., Gordon, K. C., & Das, S. C. (2020). Co-amorphization of kanamycin with amino acids improves aerosolization. Pharmaceutics, 12(8), 715. doi: 10.3390/pharmaceutics12080715
Journal - Research Article
Khadka, P., Hill, P. C., Zhang, B., Katare, R., Dummer, J., & Das, S. C. (2020). A study on polymorphic forms of rifampicin for inhaled high dose delivery in tuberculosis treatment. International Journal of Pharmaceutics, 587, 119602. doi: 10.1016/j.ijpharm.2020.119602
Journal - Research Article
Eedara, B. B., Tucker, I. G., & Das, S. C. (2019). In vitro dissolution testing of respirable size anti-tubercular drug particles using a small volume dissolution apparatus. International Journal of Pharmaceutics, 559, 235-244. doi: 10.1016/j.ijpharm.2019.01.035
Journal - Research Article
Eedara, B. B., Tucker, I. G., & Das, S. C. (2019). A STELLA simulation model for in vitro dissolution testing of respirable size particles. Scientific Reports, 9(1), 18522. doi: 10.1038/s41598-019-55164-0
Journal - Research Article
Eedara, B. B., Tucker, I. G., Zujovic, Z. D., Rades, T., Price, J. R., & Das, S. C. (2019). Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs. European Journal of Pharmaceutical Sciences, 136, 104961. doi: 10.1016/j.ejps.2019.104961
Journal - Research Article
Momin, M. A. M., Rangnekar, B., Larson, I., Sinha, S., & Das, S. C. (2019). Dry powder formulation combining bedaquiline with pyrazinamide for latent and drug-resistant tuberculosis. Advanced Powder Technology, 30(11), 2473-2482. doi: 10.1016/j.apt.2019.07.016
Journal - Research Article
Momin, M. A. M., Rangnekar, B., Sinha, S., Cheung, C.-Y., Cook, G. M., & Das, S. C. (2019). Inhalable dry powder of Bedaquiline for pulmonary tuberculosis: In vitro physiochemical characterization, antimicrobial activity and safety studies. Pharmaceutics, 11(10), 502. doi: 10.3390/pharmaceutics11100502
Journal - Research Article
Momin, M. A. M., Sinha, S., Tucker, I. G., & Das, S. C. (2019). Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis. Drug Development & Industrial Pharmacy, 45(8), 1321-1331. doi: 10.1080/03639045.2019.1609494
Journal - Research Article
Momin, M. A. M., Tucker, I. G., & Das, S. C. (2019). The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin. Drug Development & Industrial Pharmacy, 45(7), 1205-1213. doi: 10.1080/03639045.2019.1607869
Journal - Research Article
Rangnekar, B., Momin, M. A. M., Eedara, B. B., Sinha, S., & Das, S. C. (2019). Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. International Journal of Pharmaceutics, 570, 118689. doi: 10.1016/j.ijpharm.2019.118689
Journal - Research Article
Eedara, B. B., Rangnekar, B., Doyle, C., Cavallaro, A., & Das, S. C. (2018). The influence of surface active L-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders. International Journal of Pharmaceutics, 542(1-2), 72-81. doi: 10.1016/j.ijpharm.2018.03.005
Journal - Research Article
Khadka, P., Dummer, J., Hill, P. C., & Das, S. C. (2018). Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment. International Journal of Pharmaceutics, 548(1), 244-254. doi: 10.1016/j.ijpharm.2018.07.011
Journal - Research Article
Momin, M. A. M., Rangnekar, B., & Das, S. C. (2018). Development and validation of a RP-HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation. Journal of Liquid Chromatography & Related Technologies, 41(8), 415-421. doi: 10.1080/10826076.2018.1437748
Journal - Research Article
Momin, M. A. M., Tucker, I. G., & Das, S. C. (2018). High dose dry powder inhalers to overcome the challenges of tuberculosis treatment. International Journal of Pharmaceutics, 550(1-2), 398-417. doi: 10.1016/j.ijpharm.2018.08.061
Journal - Research Article
Momin, M. A. M., Tucker, I. G., Doyle, C. S., Denman, J. A., & Das, S. C. (2018). Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug. International Journal of Pharmaceutics, 543, 318-327. doi: 10.1016/j.ijpharm.2018.04.003
Journal - Research Article
Momin, M. A. M., Tucker, I. G., Doyle, C. S., Denman, J. A., Sinha, S., & Das, S. C. (2018). Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections. International Journal of Pharmaceutics, 541(1-2), 26-36. doi: 10.1016/j.ijpharm.2018.02.026
Journal - Research Article
Momin, M. A. M., Sinha, S., Tucker, I. G., Doyle, C., & Das, S. C. (2017). Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis. International Journal of Pharmaceutics, 528(1-2), 107-117. doi: 10.1016/j.ijpharm.2017.06.004
Journal - Research Article
Momin, M. A. M., Thien, S. J., Krittaphol, W., & Das, S. C. (2017). Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis. Journal of Pharmaceutical & Biomedical Analysis, 135, 133-139. doi: 10.1016/j.jpba.2016.11.046
Journal - Research Article
Das, S. C., & Stewart, P. J. (2016). The influence of lung surfactant liquid crystalline nanostructures on respiratory drug delivery. International Journal of Pharmaceutics, 514(2), 465-474. doi: 10.1016/j.ijpharm.2016.06.029
Journal - Research Article
Eedara, B. B., Tucker, I. G., & Das, S. C. (2016). Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis. International Journal of Pharmaceutics, 506(1-2), 174-183. doi: 10.1016/j.ijpharm.2016.04.038
Journal - Research Article
Das, S. C., Tucker, I. G., & Stewart, P. J. (2015). Surface energy determined by inverse gas chromatography as a tool to investigate particulate interactions in dry powder inhalers. Current Pharmaceutical Design, 21(27), 3932-3944. Retrieved from http://europepmc.org/abstract/MED/26290201
Journal - Research Article
Das, S., Tucker, I., & Stewart, P. (2015). Inhaled dry powder formulations for treating tuberculosis. Current Drug Delivery, 12(1), 26-39.
Journal - Research Article
Shi, J., Das, S., Morton, D., & Stewart, P. (2015). The kinetics of de-agglomeration of magnesium stearate dry-coated salbutamol sulphate powders. KONA Powder & Particle Journal, (32), 131-142. doi: 10.14356/kona.2015001
Journal - Research Article
Tucker, I. G., Das, S. C., & Stewart, P. J. (2015). A view on the less-than-rational development of drug delivery systems: The example of dry powder inhalers. Journal of Drug Delivery Science & Technology, 30, 310-317. doi: 10.1016/j.jddst.2015.06.008
Journal - Research Article
Allahham, A., Stewart, P. J., & Das, S. C. (2013). Improving the de-agglomeration and dissolution of a poorly water soluble drug by decreasing the agglomerate strength of the cohesive powder. International Journal of Pharmaceutics, 457(1), 101-109. doi: 10.1016/j.ijpharm.2013.09.030
Journal - Research Article
Das, S. C., Behara, S. R. B., Morton, D. A. V., Larson, I., & Stewart, P. J. (2013). Importance of particle size and shape on the tensile strength distribution and de-agglomeration of cohesive powders. Powder Technology, 249, 297-303. doi: 10.1016/j.powtec.2013.08.034
Journal - Research Article
Das, S. C., & Stewart, P. J. (2012). Characterising surface energy of pharmaceutical powders by inverse gas chromatography at finite dilution. Journal of Pharmacy & Pharmacology, 64(9), 1337-1348. doi: 10.1111/j.2042-7158.2012.01533.x
Journal - Research Article
Das, S. C., Behara, S. R. B., Bulitta, J. B., Morton, D. A. V., Larson, I., & Stewart, P. J. (2012). Powder strength distributions for understanding de-agglomeration of lactose powders. Pharmaceutical Research, 29(10), 2926-2935. doi: 10.1007/s11095-012-0799-0
Journal - Research Article
Das, S. C., Larson, I., Morton, D. A. V., & Stewart, P. J. (2011). Determination of the polar and total surface energy distributions of particulates by inverse gas chromatography. Langmuir, 27(2), 521-523. doi: 10.1021/la104135z
Journal - Research Article
Das, S. C., Zhou, Q., Morton, D. A. V., Larson, I., & Stewart, P. J. (2011). Use of surface energy distributions by inverse gas chromatography to understand mechanofusion processing and functionality of lactose coated with magnesium stearate. European Journal of Pharmaceutical Sciences, 43(4), 325-333. doi: 10.1016/j.ejps.2011.05.012
Journal - Research Article
Zhou, Q., Denman, J. A., Gengenbach, T., Das, S., Qu, L., Zhang, H., … Morton, D. A. V. (2011). Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. Journal of Pharmaceutical Sciences, 100(8), 3421-3430. doi: 10.1002/jps.22547
Journal - Research Article
Das, S., Larson, I., Young, P., & Stewart, P. (2010). Understanding lactose behaviour during storage by monitoring surface energy change using inverse gas chromatography. Dairy Science & Technology, 90(2-3), 271-285. doi: 10.1051/dst/2009051
Journal - Research Article
Tay, T., Das, S., & Stewart, P. (2010). Magnesium stearate increases salbutamol sulphate dispersion: What is the mechanism? International Journal of Pharmaceutics, 383(1-2), 62-69. doi: 10.1016/j.ijpharm.2009.09.006
Journal - Research Article
Das, S., Larson, I., Young, P., & Stewart, P. (2009). Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity. European Journal of Pharmaceutical Sciences, 37(3-4), 442-450. doi: 10.1016/j.ejps.2009.03.016
Journal - Research Article
Das, S., Larson, I., Young, P., & Stewart, P. (2009). Influence of storage relative humidity on the dispersion of salmeterol xinafoate powders for inhalation. Journal of Pharmaceutical Sciences, 98(3), 1015-1027. doi: 10.1002/jps.21500
Journal - Research Article
Das, S., Larson, I., Young, P., & Stewart, P. (2009). Surface energy changes and their relationship with the dispersibility of salmeterol xinafoate powders for inhalation after storage at high RH. European Journal of Pharmaceutical Sciences, 38(4), 347-354. doi: 10.1016/j.ejps.2009.08.007
Journal - Research Article
Das, S., Rades, T., & McDowell, A. (2023). In honor of Professor Ian Tucker. International Journal of Pharmaceutics. Advance online publication. doi: 10.1016/j.ijpharm.2023.122762
Journal - Research Other
Ameratunga, R., Woon, S.-T., Steele, R., Snell, R., Medlicott, N., Mears, E., … Das, S., … Quiñones‑Mateu, M. E. (2021). The nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. Expert Review of Clinical Immunology, 17(6), 553-560. doi: 10.1080/1744666x.2021.1912596
Journal - Research Other
Bastola, R., Young, P. M., & Das, S. C. (2021). Simulation of respiratory tract lining fluid for in vitro dissolution study. Expert Opinion on Drug Delivery, 18(8), 1091-1100. doi: 10.1080/17425247.2021.1882991
Journal - Research Other
Saha, T., Khadka, P., & Das, S. C. (2021). Alcohol-based hand sanitizer: Composition, proper use and precautions. Germs, 11(3), 408-417. doi: 10.18683/germs.2021.1278
Journal - Research Other
Ameratunga, R., Lehnert, K., Leung, E., Comoletti, D., Snell, R., Woon, S.-T., … Medlicott, N., Das, S., … Quiñones‑Mateu, M., … Jordan, A. (2020). Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. New Zealand Medical Journal, 133(1515), 112-118. Retrieved from https://www.nzma.org.nz/journal
Journal - Research Other
Das, S. C., Stewart, P. J., & Tucker, I. G. (2018). The respiratory delivery of high dose dry powders. International Journal of Pharmaceutics, 550, 486-487. doi: 10.1016/j.ijpharm.2018.09.014
Journal - Research Other